ACT001 reduces the expression of PD-L1 by inhibiting the phosphorylation of STAT3 in glioblastoma

Abstract

Our results demonstrate that STAT3 plays a key role in immunosuppression of glioma and is inhibited by ACT001. ACT001 inhibits PD-L1 transcription and modulates anti-tumor immune response in glioma bearing mice. These findings will help us to understand the mechanism of ACT001 in GBM therapy.

References 65

1. 1.

   Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017;23:6279-91.

   Not in our library10.1158/1078-0432.ccr-16-2598

2. 2.

   PD-1 related transcriptome profile and clinical outcome in diffuse gliomas. Oncoimmunology. 2018;7:e1382792.

   Not in our library10.1080/2162402x.2017.1382792

3. 3.

   Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology. 2016;5:e1196310.

   Not in our library10.1080/2162402x.2016.1196310

4. 4.

   Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. Oncoimmunology. 2017;6:e1328339.

   Not in our library10.1080/2162402x.2017.1328339

5. 5.

   Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res. 2016;22:1161-72.

   Not in our library10.1158/1078-0432.ccr-15-1516

6. 6.

   Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors. 2018.

   Not in our library

7. 7.

   Parthenolide: from plant shoots to cancer roots. Drug Discov Today. 2013;18:894-905.

   Not in our library10.1016/j.drudis.2013.05.005

8. 8.

   The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS PharmSciTech. 2007;8:E105.

   Not in our library10.1208/pt0802043

9. 9.

   Guaianolide sesquiterpene lactones, a source to discover agents that selectively inhibit acute myelogenous leukemia stem and progenitor cells. J Med Chem. 2012;55:8757-69.

   Not in our library10.1021/jm301064b

10. 10.

    Pharmacokinetics, tissue distribution and excretion of ACT001 in Sprague-Dawley rats and metabolism of ACT001. J Chromatogr B Analyt Technol Biomed Life Sci. 2019;1104:29-39.

    Not in our library10.1016/j.jchromb.2018.11.004

11. 11.

    Micheliolide derivative DMAMCL inhibits glioma cell growth in vitro and in vivo. PLoS One. 2015;10:e0116202.

    Not in our library10.1371/journal.pone.0116202

12. 12.
    The anti-tumor growth effect of a novel agent DMAMCL in rhabdomyosarcoma in vitro and in vivo · 2019

    Not checked
13. 13.

    ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF-κB activation. J Cell Biochem. 2018.

    Not in our library10.1002/jcb.27146

14. 14.

    Dimethylaminomicheliolide ameliorates peritoneal fibrosis through the activation of autophagy. J Mol Med (Berl). 2019;97:659-74.

    Not in our library10.1007/s00109-019-01757-1

15. 15.

    Micheliolide ameliorates renal fibrosis by suppressing the Mtdh/BMP/MAPK pathway. Lab Invest. 2019.

    Not in our library10.1038/s41374-019-0245-6

16. 16.

    Micheliolide suppresses LPS-induced neuroinflammatory responses. PLoS One. 2017;12:e0186592.

    Not in our library10.1371/journal.pone.0186592

17. 17.

    Antitumorigenic potential of STAT3 alternative splicing modulation. Proc Natl Acad Sci U S A. 2011;108:17779-84.

    Not in our library10.1073/pnas.1108482108

18. 18.

    Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. Theranostics. 2019;9:5478-96.

    Not in our library10.7150/thno.33444

19. 19.

    IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer. Theranostics. 2020;10:4088-100.

    Not in our library10.7150/thno.42416

20. 20.

    The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment. Mol Cell Endocrinol. 2017;451:53-65.

    Not in our library10.1016/j.mce.2017.01.004

21. 21.

    Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci Transl Med. 2018.

    Not in our library10.1126/scitranslmed.aam7729

22. 22.

    Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A. 2008;105:20852-7.

    Not in our library10.1073/pnas.0810958105

23. 23.

    Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment. Cells. 2019.

    Not in our library10.3390/cells8111398

24. 24.
    Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells · 2016

    No notice
25. 25.

    Temozolomide promotes immune escape of GBM cells via upregulating PD-L1. Am J Cancer Res. 2019;9:1161-71.

    Not in our library

26. 26.

    The interactome and spatial redistribution feature of Ca2+ receptor protein calmodulin reveals a novel role in invadopodia-mediated invasion. Cell Death Dis. 2018;9:292.

    Not in our library10.1038/s41419-017-0253-7

27. 27.
    A reproducible brain tumour model established from human glioblastoma biopsies · 2009

    Not checked
28. 28.

    PLK4 is a determinant of temozolomide sensitivity through phosphorylation of IKBKE in glioblastoma. Cancer Lett. 2019;443:91-107.

    Not in our library10.1016/j.canlet.2018.11.034

29. 29.

    Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia. J Med Chem. 2018;61:4155-64.

    Not in our library10.1021/acs.jmedchem.8b00241

30. 30.

    The role of PTRF/Cavin1 as a biomarker in both glioma and serum exosomes. Theranostics. 2018;8:1540-57.

    Not in our library10.7150/thno.22952

31. 31.

    Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343-9.

    Not in our library10.1016/j.ijrobp.2012.12.025

32. 32.

    Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018;33:152.

    Not in our library10.1016/j.ccell.2017.12.012

33. 33.

    Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.

    Not in our library10.1016/j.ccr.2009.12.020

34. 34.

    Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discov. 2018;8:1069-86.

    Not in our library10.1158/2159-8290.cd-18-0367

35. 35.

    Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86:2226-34.

    Not in our library10.1212/wnl.0000000000002770

36. 36.

    TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 2015;75:5273-82.

    Not in our library10.1158/0008-5472.can-15-0894

37. 37.

    Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.

    Not in our library10.1038/ncomms3612

38. 38.

    Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12:453-7.

    Not in our library10.1038/nmeth.3337

39. 39.

    Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier. Transl Res. 2015;166:384-98.

    Not in our library10.1016/j.trsl.2015.03.002

40. 40.

    Targeting intercellular adhesion molecule-1 prolongs survival in mice bearing bevacizumab-resistant glioblastoma. Oncotarget. 2017;8:96970-83.

    Not in our library10.18632/oncotarget.18859

41. 41.

    Small G protein Rac GTPases regulate the maintenance of glioblastoma stem-like cells in vitro and in vivo. Oncotarget. 2017;8:18031-49.

    Not in our library10.18632/oncotarget.14949

42. 42.

    PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372:311-9.

    Not in our library10.1056/nejmoa1411087

43. 43.
    Tumour-associated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth · 2017

    No notice
44. 44.

    STAT3 Establishes an Immunosuppressive Microenvironment during the Early Stages of Breast Carcinogenesis to Promote Tumor Growth and Metastasis. Cancer Res. 2016;76:1416-28.

    Not in our library10.1158/0008-5472.can-15-2770

45. 45.

    JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6:e1291106.

    Not in our library10.1080/2162402x.2017.1291106

46. 46.

    STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. Cancers (Basel). 2019.

    Not in our library10.3390/cancers11101479

47. 47.

    PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. Oncotarget. 2017;8:58457-68.

    Not in our library10.18632/oncotarget.17022

48. 48.
    Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer · 2017

    No notice
49. 49.

    Distinct PD-L1/PD1 Profiles and Clinical Implications in Intrahepatic Cholangiocarcinoma Patients with Different Risk Factors. Theranostics. 2019;9:4678-87.

    Not in our library10.7150/thno.36276

50. 50.

    PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. Leukemia. 2017;31:1633-7.

    Not in our library10.1038/leu.2017.103

51. 51.

    Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity. Theranostics. 2020;10:1033-45.

    Not in our library10.7150/thno.38137

52. 52.

    Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer. Carcinogenesis. 2009;30:1941-8.

    Not in our library10.1093/carcin/bgp227

53. 53.

    Micheliolide provides protection of mice against Staphylococcus aureus and MRSA infection by down-regulating inflammatory response. Sci Rep. 2017;7:41964.

    Not in our library10.1038/srep41964

54. 54.

    Understanding the role of cytokines in Glioblastoma Multiforme pathogenesis. Cancer Lett. 2012;316:139-50.

    Not in our library10.1016/j.canlet.2011.11.001

55. 55.

    CCL2/CCR2 signaling pathway in glioblastoma multiforme. Neurochem Int. 2017;103:1-7.

    Not in our library10.1016/j.neuint.2016.12.013

56. 56.

    Antineoplastic effects and mechanisms of micheliolide in acute myelogenous leukemia stem cells. Oncotarget. 2016;7:65012-23.

    Not in our library10.18632/oncotarget.11342

57. 57.

    Parthenolide Inhibits STAT3 Signaling by Covalently Targeting Janus Kinases. Molecules. 2018.

    Not in our library10.3390/molecules23061478

58. 58.

    NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age. Expert Rev Neurother. 2014;14:1293-306.

    Not in our library10.1586/14737175.2014.964211

59. 59.

    Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell. 2017;168:487-502.e15.

    Not in our library10.1016/j.cell.2016.12.022

60. 60.

    Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci Transl Med. 2016;8:370ra180.

    Not in our library10.1126/scitranslmed.aag2942

61. 61.
    Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy · 2019

    Corrected
62. 62.

    What made sesquiterpene lactones reach cancer clinical trials. Drug Discov Today. 2010;15:668-78.

    Not in our library10.1016/j.drudis.2010.06.002

63. 63.

    Long-term every-other-day administration of DMAMCL has little effect on aging and age-associated physiological decline in mice. Aging (Albany NY). 2019;11:2583-609.

    Not in our library10.18632/aging.101932

64. 64.
    The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy · 2018

    No notice
65. 65.

    Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20:25-39.

    Not in our library10.1038/s41577-019-0218-4

Cited by papers we hold 1

• ACT001 attenuates microglia-mediated neuroinflammation after traumatic brain injury via inhibiting AKT/NFκB/NLRP3 pathway · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.